SPAC Swiftmerge to Merge With Cardiac Device Maker HDL Therapeutics

Seeking AlphaAug 11, 2023 15:53 ET

HDL Therapeutics to Go Public in SPAC Deal

By Stephen Nakrosis Biotech company HDL Therapeutics said it would become a publicly-traded company after it agreed to a definitive merger agreement with Swiftmerge Acquisition, a blank check company

Dow JonesAug 11, 2023 14:10 ET

Swiftmerge Acquisition: $480M Combination With HDL Therapeutics to Accelerate Commercialization of Cardiovascular Disease Treatment >IVCP

Swiftmerge Acquisition: $480M Combination With HDL Therapeutics to Accelerate Commercialization of Cardiovascular Disease Treatment >IVCP

Dow JonesAug 11, 2023 13:55 ET

HDL Therapeutics to Go Public in Merger With Swiftmerge Acquisition Corp.

$480 million Business Combination to Accelerate the Commercialization of an Innovative FDA-Approved Cardiovascular Disease Treatment HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage

BusinesswireAug 11, 2023 13:54 ET

Express News | Swiftmerge Acquisition Corp. Shares To Resume Trade At 12:45 P.m. ET

Moomoo 24/7Aug 11, 2023 12:26 ET

SPAC Swiftmerge Signs LOI for Potential Merger With HDL Therapeutics

Seeking AlphaApr 26, 2023 15:02 ET